Heptares starts dosing in Phase I trial of Alzheimer ’s drug

UK-based Heptares Therapeutics has started dosing subjects in a Phase I clinical trial of HTL0016878 being developed for the treatment of neurobehavioural symptoms in Alzheimer ’s disease patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news